ZyVersa Therapeutics Announces Article Published in Peer-Reviewed Biomedical Journal Demonstrating That NLRP3 Inflammasome Inhibition Attenuates Inflammatory Bowel Disease Symptoms in Animal Model
09 nov. 2023 07h35 HE
|
ZyVersa Therapeutics
NLRP3 inflammasome inhibition attenuates intestinal inflammation and tissue damage, and significantly improves symptoms in IBD animal model.
Organovo Highlights FXR314 Combination Therapy Potential and Plan
08 nov. 2023 08h05 HE
|
Organovo, Inc.
SAN DIEGO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in ulcerative colitis and...
Asia-Pacific Anti-inflammatory Therapeutics Market to Reach $40.5 Billion by 2032 With CAGR of 5.4%: Says Allied Market Research
05 nov. 2023 18h55 HE
|
Allied Market Research
Wilmington, Delaware, Nov. 05, 2023 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled, “Asia-Pacific Anti-inflammatory Therapeutics Market, By Drug Class (Biologics, NSAIDs,...
Biora Therapeutics Submits Updated IND Application for BT-600
30 oct. 2023 16h05 HE
|
Biora Therapeutics, Inc.
Update includes supplemental information and provides additional time to complete regulatory review; company expects to remain on track with Ph1 timeline.
Inflammatory Bowel Disease Treatment Market to hit USD 39.19 Billion by 2030 | Fortune Business Insights
30 oct. 2023 07h14 HE
|
Fortune Business Insights
Pune, India, Oct. 30, 2023 (GLOBE NEWSWIRE) -- The inflammatory bowel disease treatment market revenue is set to rise from USD 26.55 billion in 2023 to USD 39.19 billion by 2030 at a CAGR of 5.7%...
Inflammatory Bowel Disease Treatment Market Size to Surpass USD 37.00 Billion by 2029, exhibiting a CAGR of 5.7%
05 oct. 2023 04h35 HE
|
Fortune Business Insights
Pune, India, Oct. 05, 2023 (GLOBE NEWSWIRE) -- The inflammatory bowel disease treatment market size was valued at USD 23.90 billion in 2021 and projected to grow USD 37.00 billion by 2029,...
Ulcerative Colitis Market Soars to $6.84 Billion in 2023, Registering a 7.7% CAGR - Unlocking Lucrative Investment Opportunities
20 sept. 2023 04h43 HE
|
Research and Markets
Dublin, Sept. 20, 2023 (GLOBE NEWSWIRE) -- The "Ulcerative Colitis Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The global ulcerative colitis market is...
First Wave BioPharma to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
05 sept. 2023 07h00 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Sept. 05, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
Fecal Calprotectin Test Market revenue to hit USD 350 Million by 2035, says Research Nester
23 août 2023 07h30 HE
|
Research Nester
New York, Aug. 23, 2023 (GLOBE NEWSWIRE) -- The global fecal calprotectin test market size is predicted to grow at a CAGR of over ~12% from 2023 to 2035. The market is projected to garner a revenue...
Fecal Calprotectin Test Market to Grow at 10.7% CAGR, Aiming for USD 355.8 Million by 2031 – TMR Report
24 mai 2023 06h30 HE
|
Transparency Market Research
Wilmington, Delaware, United States, May 24, 2023 (GLOBE NEWSWIRE) -- The global fecal calprotectin test market stood at US$ 126.9 million in 2022 and the global market is projected to reach US$...